
Investments
15Portfolio Exits
7Partners & Customers
10Service Providers
2About Abbott
Abbott (NYSE: ABT) operates as a global healthcare company. It provides a portfolio of science-based offerings in diagnostics, medical devices, nutrition, and branded generic pharmaceuticals. It was founded in 1894 and is based in Abbott Park, Illinois.

Want to inform investors similar to Abbott about your company?
Submit your Analyst Briefing to get in front of investors, customers, and partners on CB Insights’ platform.
Expert Collections containing Abbott
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Find Abbott in 2 Expert Collections, including Fortune 500 Investor list.
Fortune 500 Investor list
590 items
This is a collection of investors named in the 2019 Fortune 500 list of companies. All CB Insights profiles for active investment arms of a Fortune 500 company are included.
Conference Exhibitors
5,302 items
Research containing Abbott
Get data-driven expert analysis from the CB Insights Intelligence Unit.
CB Insights Intelligence Analysts have mentioned Abbott in 1 CB Insights research brief, most recently on Jan 27, 2023.
Latest Abbott News
Sep 29, 2023
Dublin, IRELAND Dublin, Sept. 29, 2023 (GLOBE NEWSWIRE) -- The "Neuromodulation - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering. Global Neuromodulation Market to Reach $11.6 Billion by 2030 The global market for Neuromodulation estimated at US$5.9 Billion in the year 2022, is projected to reach a revised size of US$11.6 Billion by 2030, growing at a CAGR of 8.9% over the analysis period 2022-2030. The global market for neuromodulation technologies has seen positive trends, building upon a favorable historic review from 2014 to 2021. This market encompasses various therapeutic applications, including spinal cord stimulation, deep brain stimulation, sacral nerve stimulation, vagus nerve stimulation, transcutaneous electrical nerve stimulation, repetitive transcranial magnetic stimulation, and other technologies. Spinal cord stimulation, as one of the segments analyzed in the report, is projected to achieve a substantial 15.3% compound annual growth rate (CAGR) and reach US$ Thousand in annual sales by the end of the analysis period. Likewise, other segments like deep brain stimulation and sacral nerve stimulation are expected to contribute to the market's growth with significant CAGR figures. The global neuromodulation market shows robust potential, with an estimated valuation of US$ Thousand in annual sales in 2022, forecasted to expand significantly by 2030, driven by a strong CAGR during the analysis period from 2022 to 2030. Spinal Cord Stimulation, one of the segments analyzed in the report, is projected to record 8.9% CAGR and reach US$5.1 Billion by the end of the analysis period. Growth in the Deep Brain Stimulation segment is estimated at 9.2% CAGR for the next 8-year period. In the U.S., the neuromodulation market is estimated to reach US$ Thousand in annual sales in 2022. China, as the world's second-largest economy, is forecasted to experience substantial growth, with annual sales projected to reach US$ Thousand by the year 2030, driven by a notable CAGR over the analysis period from 2022 to 2030. Other noteworthy geographic markets, including Japan and Canada, are also expected to exhibit significant growth. Within Europe, several countries are projected to contribute to the market's expansion, demonstrating promising CAGR figures. The Neuromodulation market in the U.S. is estimated at US$2.8 Billion in the year 2022. China, the world's second largest economy, is forecast to reach a projected market size of US$898.5 Million by the year 2030 trailing a CAGR of 10.6% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 8.5% and 9.1% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 8.2% CAGR. We have analyzed 83 select competitors, thereby delivering a holistic overview of the competitive landscape, including Abbott Laboratories, Inc. Coverage on global competitiveness and key competitor percentage market shares Market presence analysis across multiple geographies - Strong/Active/Niche/Trivial Online interactive peer-to-peer collaborative bespoke updates Access to digital archives and trademarked research platform Complimentary updates for one year Access to curated YouTube video transcripts of market sentiments shared by CEOs, domain experts and market influencers via interviews, podcasts, press statements and event keynotes MARKET OVERVIEW Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2022 (E) Neurological Disorders 2020 Marked as a Year of Disruption & Transformation World Economic Growth Projections (Real GDP, Annual % Change) for 2020 through 2022 Global Neuromodulation Market Buckles under COVID-19 Strain Effects of COVID-19 on the Nervous System Sheds Focus on Neuromodulation Applications GLOBAL MARKET OVERVIEW Neuromodulation Market by Segment Neuromodulation Devices by Technology Neuromodulation Market by Application US and Europe Dominate the Market Asia-Pacific and other Emerging Regions Display Impressive Growth Potential Competition Recent Market Activity Annual Incidence of Adult-Onset Neurologic Disorders in the US Rising Geriatric Population and Subsequent Growth in Prevalence of Neurological Disorders Global Population Statistics for the 65+ Age Group in Million by Geographic Region for the Years 2019, 2025, 2035 and 2050 Growing Incidence of Neurodegenerative Diseases Propels the Market for Deep Brain Stimulation Devices Global Alzheimer's Prevalence by Age Group Diagnosed Prevalence Cases of Parkinson's Disease Across Select Countries Global DBS Market by Leading Player (2020E): Market Share Breakdown of Revenues for Medtronic, Boston Scientific, and Abbott Select Available Deep Brain Stimulation Devices Available in the Market Increasing Cases of Epilepsy Drives the Demand for Vagus Nerve Stimulation Devices Epilepsy Incidence by Type (2019): Percentage Share Breakdown for Idiopathic and Symptomatic Epilepsy Symptomatic Epilepsy Incidence by Type (2019): Percentage Share Breakdown of Congenital, Degenerative, Infective, Neoplastic, Trauma, and Vascular Epilepsy Spinal Cord Injuries Propel the Demand for Spinal Cord Stimulation Devices Recent Developments in Spinal Cord Injury Treatment TENS (Transcutaneous electrical nerve stimulation devices) Market Witnesses Rapid Growth Non-Invasiveness of TMS (Transcranial Magnetic Stimulation) Propelling the adoption of TMS devices Neuromodulation Technologies to Gain Preference Over Opioids Tibial Neuromodulation to Impact Overactive Bladder Market FOCUS ON SELECT PLAYERS (Total 83 Featured) Abbott Laboratories, Inc. Axonics Modulation Technologies, Inc.
Abbott Investments
15 Investments
Abbott has made 15 investments. Their latest investment was in Bigfoot Biomedical as part of their Series B - II on March 3, 2018.

Abbott Investments Activity

Date | Round | Company | Amount | New? | Co-Investors | Sources |
---|---|---|---|---|---|---|
3/28/2018 | Series B - II | Bigfoot Biomedical | $18M | Yes | Abbott, and Undisclosed Investors | 3 |
7/30/2015 | Corporate Minority | Cephea Valve Technologies | Yes | 1 | ||
9/30/2014 | Series B | VytronUS | $31.6M | Yes | 2 | |
11/14/2007 | Series D | |||||
1/19/2007 | Series B |
Date | 3/28/2018 | 7/30/2015 | 9/30/2014 | 11/14/2007 | 1/19/2007 |
---|---|---|---|---|---|
Round | Series B - II | Corporate Minority | Series B | Series D | Series B |
Company | Bigfoot Biomedical | Cephea Valve Technologies | VytronUS | ||
Amount | $18M | $31.6M | |||
New? | Yes | Yes | Yes | ||
Co-Investors | Abbott, and Undisclosed Investors | ||||
Sources | 3 | 1 | 2 |
Abbott Portfolio Exits
7 Portfolio Exits
Abbott has 7 portfolio exits. Their latest portfolio exit was Hydra Biosciences on December 14, 2018.
Date | Exit | Companies | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Acquirer | Sources |
---|---|---|---|---|---|
12/14/2018 | Asset Sale | 2 | |||
Date | 12/14/2018 | ||||
---|---|---|---|---|---|
Exit | Asset Sale | ||||
Companies | |||||
Valuation | |||||
Acquirer | |||||
Sources | 2 |
Abbott Acquisitions
28 Acquisitions
Abbott acquired 28 companies. Their latest acquisition was Bigfoot Biomedical on September 05, 2023.
Date | Investment Stage | Companies | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Total Funding | Note | Sources |
---|---|---|---|---|---|---|
9/5/2023 | Private Equity | $162.63M | Acquired | 14 | ||
2/8/2023 | Acq - P2P | 3 | ||||
9/2/2021 | Acquired | 2 | ||||
1/16/2019 | Other | |||||
10/3/2017 |
Date | 9/5/2023 | 2/8/2023 | 9/2/2021 | 1/16/2019 | 10/3/2017 |
---|---|---|---|---|---|
Investment Stage | Private Equity | Other | |||
Companies | |||||
Valuation | |||||
Total Funding | $162.63M | ||||
Note | Acquired | Acq - P2P | Acquired | ||
Sources | 14 | 3 | 2 |
Abbott Partners & Customers
10 Partners and customers
Abbott has 10 strategic partners and customers. Abbott recently partnered with mAbxience on September 9, 2023.
Date | Type | Business Partner | Country | News Snippet | Sources |
---|---|---|---|---|---|
9/20/2023 | Licensor | Spain | Fresenius : MAbxience and Abbott enter strategic partnership mAbxience , a Fresenius , today announced a strategic partnership with Abbott to commercialize several biosimilars focusing on oncology , women 's health and respiratory diseases in emerging markets including Latin America , Southeast Asia , the Middle East , and Africa . | 1 | |
9/12/2023 | Partner | Switzerland, and United Kingdom | Abbott, Ypsomed and CamDiab team up for ‘artificial pancreas’ Through the partnership with Abbott -- he adds -- the FreeStyle Libre 3 sensor is now integrated into the mylife YpsoPump system with the mylife CamAps Fx app , expanding the possibilities of choice for doctors and patients . | 1 | |
8/8/2023 | Licensee | Canada | HealthTab™ Signs Reseller Agreement With Abbott to Support UK Expansion 08 , 2023 -- Avricore Health Inc. is pleased to announce the signing of a reseller agreement between HealthTab and Abbott . | 4 | |
6/1/2023 | Partner | ||||
5/19/2023 | Licensee |
Date | 9/20/2023 | 9/12/2023 | 8/8/2023 | 6/1/2023 | 5/19/2023 |
---|---|---|---|---|---|
Type | Licensor | Partner | Licensee | Partner | Licensee |
Business Partner | |||||
Country | Spain | Switzerland, and United Kingdom | Canada | ||
News Snippet | Fresenius : MAbxience and Abbott enter strategic partnership mAbxience , a Fresenius , today announced a strategic partnership with Abbott to commercialize several biosimilars focusing on oncology , women 's health and respiratory diseases in emerging markets including Latin America , Southeast Asia , the Middle East , and Africa . | Abbott, Ypsomed and CamDiab team up for ‘artificial pancreas’ Through the partnership with Abbott -- he adds -- the FreeStyle Libre 3 sensor is now integrated into the mylife YpsoPump system with the mylife CamAps Fx app , expanding the possibilities of choice for doctors and patients . | HealthTab™ Signs Reseller Agreement With Abbott to Support UK Expansion 08 , 2023 -- Avricore Health Inc. is pleased to announce the signing of a reseller agreement between HealthTab and Abbott . | ||
Sources | 1 | 1 | 4 |
Abbott Service Providers
2 Service Providers
Abbott has 2 service provider relationships
Service Provider | Associated Rounds | Provider Type | Service Type |
---|---|---|---|
Acq - P2P | Investment Bank | Financial Advisor | |
Service Provider | ||
---|---|---|
Associated Rounds | Acq - P2P | |
Provider Type | Investment Bank | |
Service Type | Financial Advisor |
Partnership data by VentureSource
Abbott Team
55 Team Members
Abbott has 55 team members, including , .
Name | Work History | Title | Status |
---|---|---|---|
Murray Lappe | U.S. Department of Transportation | Founder | Current |
Name | Murray Lappe | ||||
---|---|---|---|---|---|
Work History | U.S. Department of Transportation | ||||
Title | Founder | ||||
Status | Current |
Compare Abbott to Competitors

LifeScan provides diabetes management and glucose monitoring systems. The company offers a range of diabetes-related products and services, including blood glucose monitoring devices and digital health technologies, test strips, meters, lancing, and more. It primarily provides its service to the healthcare sector. It was founded in 1981 and is based in Malvern, Pennsylvania.
Pacific Diabetes Technologies provides medical devices and equipment services. It develops glucose sensor devices designed to bring continuous glucose monitoring and insulin delivery together in a single through-the-skin device. Pacific Diabetes Technologies was founded in 2013 and is based in Portland, Oregon.
Biolinq operates as a medical device company. It develops skin-applied electrochemical sensors that analyze body fluids to provide health information. The company was founded in 2012 and is based in San Diego, California.

Senseonics (NYSE: SENS) operates as a medical device startup company. It develops and commercializes transformative glucose monitoring products that enable people with diabetes. It utilizes fluorescence sensing technology for diabetes management. It was formerly known as Sensors for Medicine and Science. The company was founded in 2011 and is based in Germantown, Maryland.

Diabetes Neuromathix is an AI/Medtech startup building genuinely machine-intelligent artificial pancreas software suitable for the people who need it most: people with 'brittle' type-1 diabetes (T1D), who suffer from large-scale swings in blood glucose levels on a daily basis.

Roche Bros. is a chain grocery store that provides foods, bakery products, seafood, catering, and home delivery services. It is based in Wellesley, Massachusetts.